Dr. Zahra Mahmoudjafari previews upcoming CAR T therapies

Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, lists chimeric antigen receptor (CAR T) cell therapies that are in development.

Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, lists chimeric antigen receptor (CAR T) cell therapies that are in development.

Transcription

What CAR T therapies do you see coming and how do they differ from each other?

This is a loaded question; there are several of them. For currently approved products, we are learning how to use them earlier in the skincare lines. For the diffuse large B-cell lymphoma population, these indications and second-line therapy are expected to arrive anytime within the next week or two months.

Then, we plan to extend the indications to more important pathological states. Obviously, we’ve had a lot of great approvals with multiple myeloma products. This recent approval It was just February 28, so I think myeloma is good for a little while.

In terms of CAR T specifically, for immune effector cells, bispecifics are the next thing we’re really excited about. We are also looking at allogeneic CAR T products, which are off-the-shelf, which would significantly reduce the manufacturing time we face at this stage.

Comments are closed.